Panelists:
Adekemi Taylor, PhD, VP, Quantitive Science Services at Certara
Joab Williamson, Director of Clinical Operations, Faron Pharmaceuticals
Summary:
LI Pharma Focus America – Issue 04 (8월 31, 2024) features a panel discussion on Drug Repurposing: Unlocking New Therapeutic Possibilities with:
- Dr. Adekemi Taylor, Vice President of Quantitative Science Services at Certara.
- Joab Williamson, Director of Clinical Operations at Faron Pharmaceuticals.
Key Highlights
- Challenges:
- Convincing stakeholders and navigating legal/regulatory landscapes.
Identifying new uses, ensuring efficacy and safety, and securing funding.
- Convincing stakeholders and navigating legal/regulatory landscapes.
- Success Story:
- Ketamine repurposed for treatment-resistant depression, significantly impacting treatment options.
- Regulatory Navigation:
- Early dialogue with regulators and meticulous planning are crucial.
- Future Drivers:
- Advances in high-throughput screening, computing, and -omics data.
- Example: Eculizumab repurposed for atypical hemolytic uremic syndrome (aHUS).
- Collaboration:
- Interdisciplinary teamwork across clinical, regulatory, business, and legal fields is essential.
- Technology Impact:
- AI accelerates literature review, identifies new drug targets, and supports dose selection.
Patient Involvement
- Feedback: Guides treatment needs and identifies repurposing candidates.
- Participation: Provides critical data and real-world evidence through clinical trials.
- Communication: Ensures patient engagement and addresses concerns about drug history.
Drug repurposing holds great potential, driven by collaboration, technology, and patient involvement, to unlock new therapeutic possibilities.